Sometimes the market doesn't just shift—it gets completely rewritten. That's what's happening to WW International Inc. (WW), the weight-loss company formerly known as Weight Watchers. Once a household name with Oprah Winfrey as both its biggest cheerleader and board member, WW filed for bankruptcy earlier this year and has been struggling to find its footing ever since.
The culprit? A new generation of weight-loss drugs that's fundamentally changing how people think about shedding pounds. GLP-1 medications from pharmaceutical giants Novo Nordisk A/S (NVO) and Eli Lilly And Co. (LLY)—think Ozempic and Wegovy—have exploded in popularity, pulling consumers away from traditional diet programs and wellness subscriptions.
When Your Growth Score Takes a Beating
Growth scores measure how fast a company has been expanding its earnings and revenue over time, weighing both long-term trends and recent performance like the latest quarterly report. When you see a growth score crater suddenly, it's usually because the most recent quarter was rough enough to drag down the entire historical trajectory.
That's exactly what happened to WW International (WW).
From Boardroom Star to Struggling Survivor
WW International used to dominate the weight-loss industry. With Winfrey's star power and regular endorsements, the company seemed unstoppable. But the rise of injectable weight-loss medications has made the traditional diet-and-tracking model feel almost quaint by comparison.
After crawling out of Chapter 11 bankruptcy and getting back onto the Nasdaq earlier this year, the stock has fallen another 8.56%. That's not exactly the comeback story investors were hoping for.
The pain became especially acute this month when the company reported third-quarter earnings. Revenue dropped 10% year-over-year, and the company missed analyst expectations on both the top and bottom lines. The market's reaction was swift: WW's growth score in stock rankings collapsed from 68.77 to just 13.22 within a single week.
To put that in perspective, that's like going from a solid B-student to barely passing in the span of one bad test.
Searching for a New Identity
WW isn't going down without a fight. The company is in the middle of a turnaround effort, trying to expand beyond its traditional weight-loss roots. Recently, it launched a menopause management program as part of a broader diversification strategy. The goal is to position itself as a holistic wellness company rather than just another diet program competing against pharmaceutical solutions.
Right now, WW scores poorly on both growth and value metrics in stock rankings, though it does show some favorable long-term price trends. Whether that's enough to sustain a recovery remains to be seen, especially as the GLP-1 drug boom shows no signs of slowing down.
The bigger story here is about disruption. Sometimes entire industries get upended not by better versions of the same thing, but by completely different approaches to solving the same problem. WW built an empire on community support, point systems, and lifestyle changes. Now it's competing against a weekly injection that does the heavy lifting for you. That's a tough spot to be in, even with Oprah in your corner.
